🏢 Industry News

Partnerships, M&A, clinical readouts, approvals and financing across pharma and biotech.

2026-10-23 2 articles

2026-10-21 · 🏢Financing / valuation · STAT News · Isomorphic Labs

Isomorphic Labs' reported valuation raises the stakes for AI drug discovery

STAT's AI Prognosis column asks what Isomorphic Labs' very high valuation says about AI's role in drug development.
Separate reports describe early talks to raise new funds at a valuation of at least $40 billion, shortly after a roughly $2.1 billion round in May 2026; no financing has closed.
The column also touches on the debate over AI and the cost of care.

💡 Points

A valuation at this level prices in platform optionality, not pipeline: Isomorphic has no disclosed clinical-stage proof yet, so investors are paying for the possibility that structure-prediction AI compresses the road to a first candidate. For the rest of the sector, it raises the bar for what AI-native biotechs must show clinically, and it will pull partnering money toward the leaders. Treat the figure as talks, not a closed deal.

STAT+: What's the deal with Isomorphic Labs? ↗

2026-10-19 · 🏢Collaboration / license (AI lipid nanoparticle delivery) · Fierce Biotech · Eli Lilly / METiS TechBio

Lilly bets on Metis's AI platform for tissue-targeted lipid nanoparticles

Licensing & partnerships

Eli Lilly and Hong Kong-listed METiS TechBio agreed a collaboration worth up to about $1.1 billion to develop tissue-specific delivery technologies.
METiS contributes its AiLNP platform for ionizable lipid discovery, combining a large lipid library, screening and a lipid language model.
Metis gets a low double-digit-million upfront, plus development, regulatory and commercial milestones and single-digit tiered royalties; no candidates or indications were named.

💡 Points

The headline figure is almost all contingent, so the real signal is the low-eight-figure upfront: Lilly is buying an option on delivery chemistry, not an asset. Extra-hepatic LNP targeting is the bottleneck for genetic medicines, and Lilly keeps stacking deals around it. For competitors in LNP design, the question is whether AI-generated lipid libraries can show reproducible tissue selectivity in vivo.

Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery ↗

2026-10-22 3 articles

2026-10-21 · 🏢Regulatory approval · STAT News · GSK

GSK wins FDA approval for its hepatitis B drug

Oligonucleotides & RNA Infectious disease Regulatory, legal & approvals

STAT reports that GSK has won FDA approval for its hepatitis B drug.
The drug extended functional cures to far more patients than previous methods, according to the report.
Details beyond the headline were not available to us; the product is understood to be the antisense bepirovirsen.

💡 Points

A functional-cure label in hepatitis B is a landmark for the field, and GSK gets it with an antisense oligo, not a small molecule or antibody. The commercial question is uptake: finite treatment courses mean less recurring revenue per patient, but a large, long-diagnosed population. Watch Vir, Arbutus and the Chinese siRNA players, who now have a bar to clear.

STAT+: GSK picks up hep B drug approval ↗

2026-10-21 · 🏢Trial result · STAT News · Roivant

Roivant reports positive trial results in non-infectious uveitis

Immunology & inflammation Infectious disease Clinical readouts

STAT reports that Roivant announced positive trial results for its immune drug in non-infectious uveitis.
The result could open a new market for the drug beyond its current indications.
Only the headline and lede were available to us; the specific endpoints and data are not confirmed here.

💡 Points

Uveitis is a small but sticky indication where a non-steroid oral option is valued, and another label extension spreads development cost across more indications. The market will want to see the effect size against the standard of care, not just the win itself. I'd expect this to feed straight into Roivant's partnering and financing narrative for the asset.

STAT+: Roivant says closely watched immune drug succeeded in new eye disease ↗

2026-10-19 · 🏢Collaboration / license (ADC) · Fierce Biotech · Roche / Hansoh Pharma

Roche and Hansoh sign a second, much larger ADC collaboration

Antibody–drug conjugates Licensing & partnerships China biotech

Roche and China's Hansoh signed a collaboration on a portfolio of early-stage antibody-drug conjugates, its second ADC deal after a 2025 CDH17 ADC license.
Reports put the upfront at about $400 million plus a further $110 million after a year, with total potential payments above $15 billion and royalties.
Hansoh leads early development through global phase 1a, after which Roche takes over development outside Greater China.

💡 Points

The structure is the story: a platform-style deal where the licensor runs the work through phase 1a looks like Roche buying options on China's early ADC output rather than a single asset. A headline above $15 billion is mostly back-end milestones, so the real signal is a near-$500 million near-term cash commitment. It also keeps Roche in the race with Merck, Pfizer and AstraZeneca for Chinese ADC supply.

Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pact ↗

2026-10-21 1 article

2026-10-19 · 🏢Policy / M&A restriction · STAT News · China (regulators) / foreign acquirers of Chinese biotech

China proposes curbs on foreign acquisitions of critical biopharma technologies

Oligonucleotides & RNA Cell & gene therapy M&A China biotech

China is proposing new restrictions on foreign acquisitions of critical biopharma technologies as it seeks to keep control of its fast-growing drug development industry.
Trade coverage of the draft (Fierce) describes it as targeting full transfers of proprietary cell and gene therapy, siRNA and pathogen gain-of-function platforms, while standard out-licensing and CRO/CDMO outsourcing appear to be exempt.
The final text and timing are not confirmed.

💡 Points

If licensing really stays exempt, the draft mostly shuts the door on buying a Chinese platform company outright while leaving the license-in model that Western pharma has leaned on intact. That nudges deal structure toward options and NewCo licensing, not away from China. Buyers of cell, gene and siRNA platforms are the ones who should re-run their pipelines of targets.

STAT+: China moves to restrict foreign biotech acquisitions ↗

2026-10-20 2 articles

2026-10-19 · 🏢Trial result · STAT News · Gilead Sciences

Gilead's oral emvistegrast meets the primary endpoint in Phase 2 ulcerative colitis

Immunology & inflammation Clinical readouts

Gilead's once-daily oral α4β7 integrin inhibitor emvistegrast (GS-1427) met its primary endpoint in the Phase 2 SWIFT study in ulcerative colitis.
At the 200 mg dose, clinical remission at week 12 was roughly three times the placebo rate, with nominal significance and good tolerability.
STAT's report is paywalled; figures here follow Gilead's own statement.

💡 Points

An oral α4β7 blocker is the obvious answer to injectable vedolizumab, and a roughly 23-point placebo-adjusted remission is credible for a Phase 2. But the p-values are nominal and the arms are small, so Phase 3 and Takeda's entrenched biologic franchise, not this readout, decide whether the oral convenience story pays.

Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds ↗

2026-10-19 · 🏢M&A · Fierce Biotech · Merck KGaA / Silence Therapeutics

Merck KGaA buys Silence Therapeutics for about $1.3B after siRNA Phase 2 win

Oligonucleotides & RNA M&A

Merck KGaA will acquire Silence in an all-cash deal at $20 per ADS, an equity value of about $1.3 billion, via a UK scheme of arrangement.
The price is a 130% premium to the prior close, and Silence called it the outcome of a competitive sale process.
The deal follows positive Phase 2 data for Silence's siRNA divesiran in polycythemia vera.

💡 Points

A 130% premium for a single mid-stage asset says Merck KGaA is paying for de-risked rare-haematology data and a validated platform, not for breadth. It needs growth after its portfolio gaps, and siRNA offers a modality it can slot in. Watch whether Silence's platform survives as a standalone engine or just feeds divesiran.

Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win ↗

2026-10-19 1 article

2026-10-06 · 🏢Partnership expansion · Fierce Biotech · Eli Lilly / Gate Bioscience

Lilly roughly doubles its Gate Bioscience Sec61 pact, to up to $870M

Licensing & partnerships

Lilly expanded its collaboration with Gate Bioscience to a potential value of up to $870M, from the original 2025 pact worth up to $856M.
The expansion adds one target, with an option on a second; Gate gets an upfront payment, further payment if a second target is chosen, research funding and milestones.
Gate's platform works on Sec61, the channel through which secreted and membrane proteins exit the cell; targets and indications are undisclosed.

💡 Points

An expansion rather than a new deal is the real signal: Lilly saw enough from the first target to pay for another. With Pfizer following into Sec61 with Enodia a week later, a small-molecule channel-modulation approach to 'undruggable' secreted proteins is turning into a crowded field. Undisclosed upfront and targets make the economics hard to judge.

Gate CEO sees expanded $870M Lilly pact as 'vote of confidence' ↗

2026-10-18 1 article

2026-10-15 · 🏢Asset sale / divestiture · Fierce Biotech · Lakefront Biotherapeutics (formerly Galapagos) / Armed Cell Therapeutics

Lakefront offloads its shelved CAR-T pipeline to Stoffels-backed Armed Cell

Cell & gene therapy M&A

Lakefront Biotherapeutics, the former Galapagos, is selling its abandoned cell therapy programs to Armed Cell Therapeutics, a new Belgian company co-founded and chaired by ex-Galapagos CEO Paul Stoffels.
Reported terms are a small upfront payment (single-digit millions of euros) plus up to roughly $230 million in milestones.
The package covers two armed CAR-Ts nearing the clinic in non-Hodgkin lymphoma and small cell lung cancer, plus three early preclinical projects.

💡 Points

A tiny upfront against a long milestone tail is what a buyer pays for preclinical assets nobody else wanted: the risk stays with Armed Cell, and Lakefront gets optionality without cost. For Lakefront, the signal is a clean pivot to autoimmune T-cell engagers. The open question is whether Armed Cell, run by the man who started the CAR-T bet, can fund the clinic.

Rebranded Galapagos finally finds buyer for unwanted cell therapy pipeline ↗

2026-10-17 3 articles

2026-10-16 · 🏢Regulatory milestone · STAT News · Revolution Medicines

European regulators recommend Revolution Medicines' Rasonque for pancreatic cancer

Oncology RAS pathway Regulatory, legal & approvals

Following FDA approval, European regulators have recommended approval of Revolution Medicines' Rasonque (daraxonrasib) for pancreatic cancer, per STAT+.
The recommendation moves the RAS(ON) inhibitor toward a second major market.
This summary rests on the article's teaser; a separate search could not confirm the EU opinion.

💡 Points

If confirmed, a quick EU follow-on after the US nod shows how fast an oral RAS(ON) inhibitor with a clear survival benefit in a deadly cancer can move. For analysts the questions now shift to pricing, reimbursement and label expansion beyond second-line pancreatic disease. It also validates the tri-complex approach for peers still chasing KRAS in the same tumor type.

STAT+: RevMed's pancreatic cancer drug nears European approval ↗

2026-10-15 · 🏢Research collaboration · Fierce Biotech · AstraZeneca / insitro

AstraZeneca pays insitro $40M upfront for AI-driven liver and heart target discovery

Licensing & partnerships

AstraZeneca and insitro signed a collaboration to find novel drug targets for liver and heart diseases using AI.
Reported terms: a modest upfront payment of $40 million, with milestones taking the total to about $1.5 billion.
Terms come from search-snippet reporting of the Fierce Biotech article, which could not be opened directly.

💡 Points

A small upfront against a large biobucks headline is the standard shape for platform-style target discovery: AstraZeneca pays for optionality, not assets. The partner choice shows where AZ sees the pharmacology bottleneck, in picking targets rather than designing molecules. I'd read it as another hedge alongside its other AI deals; the payoff comes only if the targets are credible.

AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs ↗

2026-10-15 · 🏢Pipeline progress · STAT News · Merck / Moderna

Merck and Moderna say their mRNA cancer vaccine plan still needs a lot of exploring

Oligonucleotides & RNA Oncology

At the STAT Summit, Moderna's Stephen Hoge and Merck's Dean Li discussed pairing Keytruda with personalized mRNA cancer vaccines.
Both executives framed the first positive results as a start, with much left to work out.
This summary rests on the article's teaser, not the full text.

💡 Points

Pairing a personalized vaccine with Keytruda protects Merck's franchise as PD-1 exclusivity ages, so Merck has a strategic reason beyond the science. The executives' caution about what comes next is telling: the open questions are tumor types, dosing settings and manufacturing scale. Rivals with other neoantigen approaches should read it as a bar to clear.

Merck and Moderna have 'lot of exploring to do' after initial cancer vaccine success ↗

2026-10-16 5 articles

2026-10-15 · 🏢Clinical data update · STAT News · Verastem Oncology

Verastem reports encouraging early data for its oral KRAS G12D inhibitor in pancreatic cancer

Oncology RAS pathway Clinical readouts

Verastem presented early results for its KRAS G12D inhibitor, studied in more than 200 patients with advanced solid tumors including metastatic pancreatic cancer and others.
Other coverage describes anti-tumor activity and a manageable safety profile across pancreatic, colorectal and lung cancers.
This summary rests on the public lead of a paywalled STAT piece plus secondary reports, so details are limited.

💡 Points

KRAS G12D in pancreatic cancer is the biggest open space after G12C, and early activity with clean liver safety is what the field needs to see. The competitive question is durability against other G12D programs, including those from large players. Registration-directed Phase 2 trials and Fast Track status give Verastem a credible path, but single-arm early data can flatter.

STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer ↗

2026-10-14 · 🏢Licensing / collaboration · Fierce Biotech · Gilead / Vir Biotechnology

Gilead licenses three dual-masked T-cell engagers from Vir in a deal worth up to about $1.9B

Antibodies & biologics Oncology Licensing & partnerships

Vir will discover, design and optimize three T-cell engagers against solid-tumor antigens on its dual-masked PRO-XTEN platform; Gilead holds exclusive rights to nominate candidates and then develops and commercializes them.
Vir receives $90M up front ($65M cash plus a $25M equity investment) and $45M in near-term preclinical milestones.
Up to $1.74B in development, regulatory and commercial milestones and tiered royalties could follow.

💡 Points

This is Gilead's third T-cell engager move in a short stretch (Merus, Ouro, now Vir), so the oncology thesis is clearly masked, conditional-activation TCEs for solid tumors. For Vir, it's the second platform deal this year and non-dilutive cash that lets it fund its own pipeline; the equity premium shows Gilead's commitment. Preclinical risk stays high.

Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs ↗

2026-10-14 · 🏢Research collaboration · Fierce Biotech · Zealand Pharma / Generate Biomedicines

Zealand pays $30M upfront for Generate's AI-designed multispecific proteins in obesity

Metabolic disease & obesity Licensing & partnerships

Generate will use its AI platform to design multispecific proteins for obesity and metabolic disease, leading research to lead-candidate selection.
Zealand then takes over clinical development, regulatory work and commercialization, starting with two programs and an option on a third.
Reported terms: $30M upfront, up to $35M of early preclinical milestones and nearly $1.2B in total milestones plus tiered royalties.

💡 Points

Zealand already has Roche and Boehringer on its obesity assets, and this adds a third modality bet, AI-designed biologics, with a small upfront. The structure keeps risk on Generate until a lead exists. For Generate, it's another big-pharma-style validation after Novartis and Amgen, although multispecifics in obesity are still unproven clinically.

Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline ↗

2026-10-13 · 🏢Licensing / collaboration · Fierce Biotech · Pfizer / Enodia Therapeutics

Pfizer partners with Enodia on Sec61 inhibitors in a deal worth over $500M

Licensing & partnerships

Enodia will use its platform to find and develop Sec61 inhibitors against several targets; Pfizer takes on clinical, manufacturing, regulatory and commercial work.
The upfront is undisclosed; R&D and sales milestones could push the total above $500M, with tiered royalties on top.
It follows Lilly's deal with Gate Bioscience in the same Sec61 space, reportedly worth about $870M.

💡 Points

Sec61 is a hard target: it is a core translocon, and the chemistry has to block only disease-linked proteins without general toxicity. Two big pharmas moving within a week suggests selectivity data are persuasive behind closed doors, but the undisclosed upfront and targets mean the real signal is still thin. Watch which client proteins each company is going after.

Pfizer pens $500M Enodia pact to join Lilly in emerging protein degrader field ↗

2026-10-13 · 🏢Licensing deal · Fierce Biotech · Roche / Rona Therapeutics

Roche licenses Rona's ALK7-targeting RNAi obesity candidate in a deal worth up to $1.16B

Oligonucleotides & RNA Metabolic disease & obesity Licensing & partnerships

Roche gets an exclusive license to Rona Therapeutics' investigational ALK7-targeting RNAi candidate for obesity.
Terms: up to $100M in upfront and near-term milestones, plus up to $1.06B in longer-term milestones and tiered royalties.
The program's codename and development stage were not disclosed.

💡 Points

ALK7 is the second hot RNAi obesity target after GSK's earlier SiranBio deal, and Roche says it wants to be a top-three obesity player, so this is portfolio-building on the cheap: small upfront, back-loaded milestones. It's also Roche's fifth deal with a Chinese drugmaker since late August, a sign that the best-priced early assets are still found there.

Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race ↗

2026-10-15 1 article

2026-10-14 · 🏢Regulatory / antitrust settlement · STAT News · Sanofi

Sanofi settles EU antitrust probe over disparaging a rival flu vaccine, no fine

Regulatory, legal & approvals

EU antitrust regulators accepted concessions from Sanofi to close a probe into an allegedly misleading campaign that disparaged a rival flu vaccine.
Because the case ended on accepted commitments, Sanofi avoids a fine.
Details of the commitments are behind STAT's paywall; this summary rests on the public excerpt only.

💡 Points

A commitments decision is the cheap exit: no infringement finding, no fine, and little disruption to the flu franchise's commercial playbook. The wider signal is that regulators are watching comparative vaccine messaging, so rivals' medical-affairs and marketing teams will likely be more careful about how they position products against competitors.

STAT+: Sanofi avoids fine as EU accepts offer to end antitrust probe over disparaging rival vaccine ↗

2026-10-14 1 article

2026-10-13 · 🏢Safety / commercial risk · STAT News · Neurocrine Biosciences

Patient advocates press safety concerns over Neurocrine's Prader-Willi drug Vykat XR

Neuroscience

STAT reports growing alarm among patient advocates and some experts over the perceived risks of Neurocrine's rare disease drug Vykat XR (diazoxide choline) for Prader-Willi syndrome.
Earlier coverage links the concern to fluid retention, respiratory and cardiac events in post-marketing reports, though causality has not been established.
Neurocrine has said it keeps a favourable benefit-risk view and is working with the FDA and patient groups.

💡 Points

This is a launch-curve story. Neurocrine paid heavily for Vykat XR as a blockbuster hopeful, and prescriber caution in a small, fragile patient population can slow uptake long before any regulatory action. The key variables are whether the label changes and whether the planned 2027 study in higher-risk patients reassures.

STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug ↗

2026-10-12 2 articles

2026-10-09 · 🏢Clinical update · STAT News · Life Biosciences

Life Biosciences reports three glaucoma patients dosed with reprogramming therapy

Clinical readouts

Life Biosciences said three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug.
No serious adverse events were reported so far.
Only the public lede was readable, so dose, follow-up length and efficacy readouts are unverified here.

💡 Points

Three patients with no serious events is a safety whisper, not a signal, but epigenetic reprogramming in humans is so new that every clean cohort moves the field's risk perception. The meaningful tests are duration of follow-up and any visual-function readout; until then this is a platform story, not a pipeline one.

STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug ↗

2026-10-08 · 🏢M&A · FiercePharma · Viatris / Pacira BioSciences

Viatris to buy Pacira for about $1.65B to add non-opioid pain franchise

Neuroscience GPCRs M&A

Viatris agreed to acquire Pacira BioSciences in an all-cash deal at $36.50 per share, a premium of roughly 45% to the last close.
The prize is Pacira's non-opioid products EXPAREL for post-surgical pain and ZILRETTA for knee osteoarthritis pain, plus a knee OA gene therapy candidate.
Closing is expected by the end of 2026, funded mainly from cash on hand.

💡 Points

This is Viatris buying a commercial pain franchise rather than science, which fits its pivot from generics toward branded cash flow. The pairing with its pending fast-acting meloxicam decision hints at a non-opioid pain sales force, though EXPAREL's generic-style competition is the long-term risk to watch.

Viatris to snap up Pacira's non-opioid pain pipeline for $1.65B ↗

2026-10-10 2 articles

2026-10-08 · 🏢Trial result (phase 3 failure) · STAT News · argenx

Argenx's Vyvgart fails to beat placebo in Phase 3 Sjögren's study

Clinical readouts

STAT reports that argenx said its blockbuster drug Vyvgart did not outperform placebo in a Phase 3 trial in patients with Sjögren's disease, a chronic autoimmune disorder.
STAT frames it as an unusual setback for a franchise that has mostly succeeded in label expansion; detailed data were not visible in the public lede.

💡 Points

Sjögren's was pitched as one of the larger expansion opportunities, so this trims the long-term sales ceiling without touching the core neuromuscular franchise. It also muddies the read-across for other Sjögren's programs: if FcRn blockade alone is not enough, bets on mechanisms that hit the disease upstream, such as Amgen's dazodalibep, look relatively better.

STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease ↗

2026-10-06 · 🏢Trial result (phase 3 miss) · Fierce Biotech · ArriVent BioPharma

ArriVent's first-line EGFR exon 20 NSCLC phase 3 misses its primary endpoint

Oncology Kinases Clinical readouts

Fierce Biotech reports that ArriVent's phase 3 FURVENT trial of the EGFR inhibitor firmonertinib missed its primary progression-free survival endpoint by blinded central review in first-line EGFR exon 20 insertion NSCLC.
The higher dose showed only a modest numerical edge over platinum chemotherapy and the lower dose did numerically worse, while investigator-assessed results looked more favorable.
ArriVent's shares fell sharply on the news.

💡 Points

A small central-review margin over chemo, in a setting where J&J's Rybrevant-plus-chemo regimen has already set a higher bar, leaves firmonertinib hard to position in exon 20. The investigator-versus-central gap gives ArriVent a regulatory conversation but a thin commercial story. The PACC-mutation ALPACCA study now looks like the company's real value driver.

ArriVent's phase 3 lung cancer trial flops, sinking stock ↗

2026-10-09 3 articles

2026-10-08 · 🏢Partnership / discovery deal · STAT News · Roche / Defand Therapeutics

Roche signs molecular glue discovery deal with China's Defand Therapeutics

Targeted protein degradation Licensing & partnerships China biotech

STAT reports Roche has signed a drug discovery deal with Chinese biotech Defand Therapeutics focused on molecular glue medicines.
Only the public lede of the STAT+ article could be read, so financial terms and targets are unverified here.

💡 Points

Roche keeps adding molecular glue partners rather than betting on one platform, and sourcing from Chinese biotechs fits the wider licensing trend. Without upfront and milestone figures I'd treat this as a discovery-stage option play, with the real signal being which targets and how many are named.

STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines ↗

2026-10-07 · 🏢Financing / venture fundraise · STAT News · Forbion

Forbion closes $2.6B, its largest fundraise and among Europe's biggest in years

Financing & IPOs

STAT reports European venture firm Forbion has raised $2.6 billion, its largest fundraise to date.
It is described as one of the largest in the region in recent years; fund structure and allocation were not visible in the public lede.

💡 Points

A raise this size from a specialist investor says LPs still back biotech formation despite a choppy funding climate, and it gives European startups a deeper home-market option. The things to watch are the split between early-stage company creation and later rounds, and whether it pulls US-bound founders toward European listings.

STAT+: Forbion raises $2.6 billion, its largest fundraise to date ↗

2026-10-07 · 🏢Litigation / legal setback · STAT News · Merck

Dutch court halts Merck's subcutaneous Keytruda in several European countries

Oncology Regulatory, legal & approvals

STAT reports a Dutch court ordered Merck to stop manufacturing and marketing its subcutaneous Keytruda formulation in several European countries.
Only the public lede was readable, so the plaintiff, grounds and scope are unverified here.

💡 Points

Subcutaneous Keytruda is Merck's main defense against the coming pembrolizumab biosimilar era, so any European delay hits that lifecycle plan directly. How long the order lasts and whether it is overturned on appeal matters more than the headline, and the case echoes the broader fight over SC hyaluronidase formulation patents.

STAT+: Merck suffers a setback in Europe over its new Keytruda formulation ↗

2026-10-08 2 articles

2026-10-07 · 🏢Discontinuation / wind-down · STAT News · Caribou Biosciences

Caribou Biosciences winds down after failing to fund late-stage CAR-T trial

Cell & gene therapy Oncology Financing & IPOs Restructuring & discontinuations

STAT reports the Doudna co-founded company is shutting down after failing to raise the money needed for a late-stage trial of its off-the-shelf CAR-T therapy for lymphoma.
Other coverage describes the company stopping development of its two clinical cell therapy candidates and cutting most staff while exploring a merger or sale.
Only the public STAT+ summary was available, so details beyond that are unverified.

💡 Points

A flagship CRISPR-era CAR-T name folding over a funding gap says the off-the-shelf cell therapy thesis is struggling to raise money against autologous products and bispecifics. It reads more as a financing failure than a clean scientific verdict, so watch whether the assets and data find a buyer.

STAT+: Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down ↗

2026-10-06 · 🏢R&D site opening / investment · STAT News · AstraZeneca

AstraZeneca opens $1B Kendall Square R&D site amid China dealmaking wave

China biotech

AstraZeneca opened a new R&D site in Boston's Kendall Square, marking a $1 billion investment.
STAT frames the opening against a backdrop of heavy dealmaking with Chinese biotechs and uncertainty in the US biotech hub.
Only the public STAT+ summary was available; site scope and headcount are not verified.

💡 Points

Planting a $1B flag in Kendall Square while licensing heavily from China looks like hedging: keep US discovery talent close even as external innovation shifts east. It's a capex signal, not a pipeline one, so the tell is whether the site hosts internal discovery or mostly integrates in-licensed assets.

STAT+: AstraZeneca opens new Boston site ↗

Industry News archive →